GATA2 and prostate carcinoma: The same phenomenon was found in additional benign TA prostate cells, i.e., PrEC, EP156T and RWPE-1 cells, but not in LNCaP or VCaP prostate cancer cell lines, in which GATA2 protein levels did not increase substantially due to MG132 treatment.